{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:44:03Z","timestamp":1787244243837,"version":"build-2736575974"},"reference-count":177,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>AML is a malignant disease of hematopoietic progenitor cells with unsatisfactory treatment outcome, especially in patients that are ineligible for intensive chemotherapy. Immunotherapy, comprising checkpoint inhibition, T-cell engaging antibody constructs, and cellular therapies, has dramatically improved the outcome of patients with solid tumors and lymphatic neoplasms. In AML, these approaches have been far less successful. Discussed reasons are the relatively low mutational burden of AML blasts and the difficulty in defining AML-specific antigens not expressed on hematopoietic progenitor cells. On the other hand, epigenetic dysregulation is an essential driver of leukemogenesis, and non-selective hypomethylating agents (HMAs) are the current backbone of non-intensive treatment. The first clinical trials that evaluated whether HMAs may improve immune checkpoint inhibitors\u2019 efficacy showed modest efficacy except for the anti-CD47 antibody that was substantially more efficient against AML when combined with azacitidine. Combining bispecific antibodies or cellular treatments with HMAs is subject to ongoing clinical investigation, and efficacy data are awaited shortly. More selective second-generation inhibitors targeting specific chromatin regulators have demonstrated promising preclinical activity against AML and are currently evaluated in clinical trials. These drugs that commonly cause leukemia cell differentiation potentially sensitize AML to immune-based treatments by co-regulating immune checkpoints, providing a pro-inflammatory environment, and inducing (neo)-antigen expression. Combining selective targeted epigenetic drugs with (cellular) immunotherapy is, therefore, a promising approach to avoid unintended effects and augment efficacy. Future studies will provide detailed information on how these compounds influence specific immune functions that may enable translation into clinical assessment.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1269012","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T06:15:34Z","timestamp":1695363334000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Epigenetic targeting to enhance acute myeloid leukemia-directed immunotherapy"],"prefix":"10.3389","volume":"14","author":[{"given":"Johanna","family":"Rausch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Ullrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.M.","family":"K\u00fchn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004583","article-title":"Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia","volume":"136","author":"R\u00f6llig","year":"2020","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33458","article-title":"De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01884-2","article-title":"Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia","volume":"37","author":"Rausch","year":"2023","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"New Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.7501","article-title":"Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML)","volume":"38","author":"Dinardo","year":"2020","journal-title":"JCO"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell\u2013engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti\u2013PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"New Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"0105","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"53","author":"Topalian","year":"2014","journal-title":"JCO"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non\u2013small-cell lung cancer with PD-L1 tumor proportion score \u2265 50%","volume":"39","author":"Reck","year":"2021","journal-title":"JCO"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"New Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"New Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"New Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01253-x","article-title":"T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments","volume":"35","author":"Daver","year":"2021","journal-title":"Leukemia"},{"key":"B32","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.leukres.2010.02.004","article-title":"The DNA demethylating agent 5-aza-2\u2032-deoxycytidine induces expression of NY-ESO-1 and other cancer\/testis antigens in myeloid leukemia cells","volume":"34","author":"Almstedt","year":"2010","journal-title":"Leukemia Res"},{"key":"B36","article-title":"Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2\u2019-deoxycytidine","volume":"54","author":"Weber","year":"1994","journal-title":"Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1112635","article-title":"Targeting epigenetic readers in cancer","volume":"367","author":"Dawson","year":"2012","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"a019505","DOI":"10.1101\/cshperspect.a019505","article-title":"Epigenetic determinants of cancer","volume":"8","author":"Baylin","year":"2016","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000673","article-title":"Next generation epigenetic modulators to target myeloid neoplasms","volume":"28","author":"Sasca","year":"2021","journal-title":"Curr Opin Hematol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01218-0","article-title":"Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies","volume":"35","author":"Stomper","year":"2021","journal-title":"Leukemia"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.3390\/cancers11111794","article-title":"HDAC inhibitors in acute myeloid leukemia","volume":"11","author":"San Jos\u00e9-En\u00e9riz","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.877134","article-title":"A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study","volume":"55","author":"Kirschbaum","year":"2014","journal-title":"Leuk Lymph."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.172411","article-title":"Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trials","volume":"103","author":"Schlenk","year":"2018","journal-title":"Haematologica"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30949","article-title":"Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic Malignancies","volume":"123","author":"Abaza","year":"2017","journal-title":"Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30532","article-title":"Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel","volume":"123","author":"Stahl","year":"2017","journal-title":"Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29085","article-title":"Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia","volume":"121","author":"Issa","year":"2015","journal-title":"Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2510","article-title":"Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American intergroup study SWOG S1117","volume":"35","author":"Sekeres","year":"2017","journal-title":"J Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2005.06.027","article-title":"The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription","volume":"19","author":"Jang","year":"2005","journal-title":"Mol Cell"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2015.04.011","article-title":"BET bromodomain inhibition suppresses the function of hematopoietic transcription factors in acute myeloid leukemia","volume":"58","author":"Roe","year":"2015","journal-title":"Mol Cell"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-018-0165-5","article-title":"Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells","volume":"9","author":"Fiskus","year":"2019","journal-title":"Blood Cancer J"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33590","article-title":"A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed\/refractory acute myeloid leukemia","volume":"127","author":"Borthakur","year":"2021","journal-title":"Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ccr.2011.06.010","article-title":"MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L","volume":"20","author":"Bernt","year":"2011","journal-title":"Cancer Cell"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0237","article-title":"Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia","volume":"6","author":"K\u00fchn","year":"2016","journal-title":"Cancer Discovery"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-818948","article-title":"The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/s41594-019-0313-z","article-title":"PRMT5 methylome profiling uncovers a direct link to splicing regulation in acute myeloid leukemia","volume":"26","author":"Radzisheuskaya","year":"2019","journal-title":"Nat Struct Mol Biol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"199","DOI":"10.15698\/cst2020.08.228","article-title":"PRMT5 function and targeting in cancer","volume":"4","author":"Kim","year":"2020","journal-title":"Cell Stress"},{"key":"B59","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/leu.2017.206","article-title":"Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML","volume":"32","author":"Kaushik","year":"2018","journal-title":"Leukemia"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.308","article-title":"The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation","volume":"30","author":"Tarighat","year":"2016","journal-title":"Leukemia"},{"key":"B61","doi-asserted-by":"publisher","first-page":"58","DOI":"10.36401\/JIPO-22-1","article-title":"Protein arginine methyltransferase 5 (PRMT5) inhibitors in oncology clinical trials: A review","volume":"5","author":"Feustel","year":"2022","journal-title":"J Immunother Precis Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1182\/blood-2021-150938","article-title":"A phase 1 dose escalation study of protein arginine methyltransferase 5 (PRMT5) inhibitor PRT543 in patients with myeloid malignancies","volume":"138","author":"Patel","year":"2021","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02276-0","article-title":"Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors","volume":"129","author":"El-Khoueiry","year":"2023","journal-title":"Br J Cancer."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.3008","article-title":"A phase 1 study of the protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor PRT811 in patients (pts) with recurrent high-grade glioma or uveal melanoma (UM)","volume":"41","author":"Monga","year":"2023","journal-title":"JCO"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1182\/blood-2019-130337","article-title":"A phase I\/II study to investigate the safety and clinical activity of the protein arginine methyltransferase 5 inhibitor GSK3326595 in subjects with myelodysplastic syndrome and acute myeloid leukemia","volume":"134","author":"Watts","year":"2019","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.3390\/cells9071639","article-title":"EZH2 in myeloid Malignancies","volume":"9","author":"Rinke","year":"2020","journal-title":"Cells"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/nature09784","article-title":"The Polycomb complex PRC2 and its mark in life","volume":"469","author":"Margueron","year":"2011","journal-title":"Nature"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat Genet"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30451-4","article-title":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study","volume":"21","author":"Gounder","year":"2020","journal-title":"Lancet Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20181276","article-title":"Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML","volume":"216","author":"Basheer","year":"2019","journal-title":"J Exp Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nm.4247","article-title":"Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia","volume":"23","author":"G\u00f6llner","year":"2017","journal-title":"Nat Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2344","article-title":"Evolution of cytogenetically normal acute myeloid leukemia during therapy and relapse: an exome sequencing study of 50 patients","volume":"24","author":"Greif","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","first-page":"5838","DOI":"10.1038\/s41598-021-84708-6","article-title":"Loss-of-function mutations in the histone methyltransferase EZH2 promote chemotherapy resistance in AML","volume":"11","author":"Kempf","year":"2021","journal-title":"Sci Rep"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-1297","article-title":"Targeting chemotherapy to decondensed H3K27me3-marked chromatin of AML cells enhances leukemia suppression","volume":"82","author":"Porazzi","year":"2022","journal-title":"Cancer Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-581082","article-title":"Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia","volume":"125","author":"Xu","year":"2015","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-807024","article-title":"LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C\/EBP\u03b1-dependent enhancers in AML","volume":"131","author":"Cusan","year":"2018","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-168945","article-title":"Iadademstat combination with azacitidine is a safe and effective treatment in first line acute myeloid leukemia. Final results of the alice trial","volume":"140","author":"Salamero","year":"2022","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.ccell.2018.02.002","article-title":"ORY-1001, a potent and selective covalent KDM1A inhibitor, for the treatment of acute leukemia","volume":"33","author":"Maes","year":"2018","journal-title":"Cancer Cell"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1126\/science.1234769","article-title":"Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation","volume":"340","author":"Wang","year":"2013","journal-title":"Science"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.7012","article-title":"Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine","volume":"41","author":"De Botton","year":"2023","journal-title":"JCO"},{"key":"B87","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccell.2015.02.016","article-title":"Pharmacologic inhibition of the menin-MLL interaction blocks progression of MLL leukemia in vivo","volume":"27","author":"Borkin","year":"2015","journal-title":"Cancer Cell"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1172\/JCI129126","article-title":"Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia","volume":"130","author":"Klossowski","year":"2020","journal-title":"J Clin Invest"},{"key":"B89","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1126\/science.aax5863","article-title":"Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia","volume":"367","author":"Uckelmann","year":"2020","journal-title":"Science"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000968924.19161.da","article-title":"P504 updated data for ziftomenib in patients with npm1-mutated relapsed or refractory acute myeloid leukemia","volume":"7","author":"Fathi","year":"2023","journal-title":"Hemasphere"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00603-3","article-title":"Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)","volume":"12","author":"Fiskus","year":"2022","journal-title":"Blood Cancer J"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.282160","article-title":"Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax","volume":"27","author":"Rausch","year":"2023","journal-title":"Haematologica"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005037","article-title":"Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition","volume":"136","author":"Dzama","year":"2020","journal-title":"Blood"},{"key":"B95","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1182\/blood.V128.22.2900.2900","article-title":"Defining the immune checkpoint landscape in patients (pts) with acute myeloid leukemia (AML)","volume":"128","author":"Daver","year":"2016","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nat Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-310425","article-title":"Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia","volume":"117","author":"Zhou","year":"2011","journal-title":"Blood"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5549","article-title":"Upregulation of Tim-3 is associated with poor prognosis in acute myeloid leukemia","volume":"12","author":"Wu","year":"2023","journal-title":"Cancer Med"},{"key":"B99","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.clim.2017.08.021","article-title":"CD8+T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients","volume":"190","author":"Wang","year":"2018","journal-title":"Clin Immunol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/tan.13872","article-title":"The immune checkpoints Cytotoxic T lymphocyte antigen-4 and Lymphocyte activation gene-3 expression is up-regulated in acute myeloid leukemia","volume":"96","author":"Radwan","year":"2020","journal-title":"HLA"},{"key":"B101","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-020-00853-x","article-title":"Expression patterns of immune checkpoints in acute myeloid leukemia","volume":"13","author":"Chen","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31896","article-title":"The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia","volume":"125","author":"Williams","year":"2019","journal-title":"Cancer"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4079","article-title":"Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic Malignancies","volume":"14","author":"Berger","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B104","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1182\/blood-2018-99-118577","article-title":"PD-L1 blockade with atezolizumab in higher-risk myelodysplastic syndrome: an initial safety and efficacy analysis","volume":"132","author":"Gerds","year":"2018","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1182\/blood.V128.22.345.345","article-title":"Pembrolizumab, a PD-1 inhibitor, in patients with myelodysplastic syndrome (MDS) after failure of hypomethylating agent treatment","volume":"128","author":"Garcia-Manero","year":"2016","journal-title":"Blood"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.30163","article-title":"Novel fully human anti-CD47 antibodies stimulate phagocytosis and promote elimination of AML cells","volume":"236","author":"Wang","year":"2021","journal-title":"J Cell Physiol"},{"key":"B108","article-title":"Initial Phase 1 results of the first-in-class anti-CD47 antibody HU5F9- G4 in relapsed\/refractory acute myeloid leukemia patients","volume-title":"EHA Library","author":"Vyas","year":"2018"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.7508","article-title":"Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed\/refractory acute myeloid leukemia (R\/R AML)","volume":"38","author":"Ravandi","year":"2020","journal-title":"JCO"},{"key":"B110","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1182\/blood-2019-127977","article-title":"Preliminary results from a phase 1 first-in-human study of AMG 673, a novel half-life extended (HLE) anti-CD33\/CD3 biTE\u00ae (Bispecific T-cell engager) in patients with relapsed\/refractory (R\/R) acute myeloid leukemia (AML)","volume":"134","author":"Subklewe","year":"2019","journal-title":"Blood"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1182\/blood-2018-99-111529","article-title":"Phase 1 first-in-human trial of AMV564, a bivalent bispecific (2x2) CD33\/CD3 T-cell engager, in patients with relapsed\/refractory acute myeloid leukemia (AML)","volume":"132","author":"Westervelt","year":"2018","journal-title":"Blood"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"key":"B113","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1182\/blood-2018-99-119786","article-title":"Complete responses in relapsed\/refractory acute myeloid leukemia (AML) patients on a weekly dosing schedule of xmAb14045, a CD123 x CD3 T cell-engaging bispecific antibody: initial results of a phase 1 study","volume":"132","author":"Ravandi","year":"2018","journal-title":"Blood"},{"key":"B114","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.3390\/ijms18112259","article-title":"Development of A chimeric antigen receptor targeting C-type lectin-like molecule-1 for human acute myeloid leukemia","volume":"18","author":"Laborda","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000322","article-title":"WT1, PRAME, and PR3 mRNA expression in acute myeloid leukemia (AML)","volume":"43","author":"Steger","year":"2020","journal-title":"J Immunother."},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-791202","article-title":"Safety and persistence of WT1-specific T-cell receptor gene\u2013transduced lymphocytes in patients with AML and MDS","volume":"130","author":"Tawara","year":"2017","journal-title":"Blood"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402988","article-title":"WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies","volume":"17","author":"Rosenfeld","year":"2003","journal-title":"Leukemia"},{"key":"B118","volume-title":"Update from the ongoing Phase I multinational study of MCLA-117, a bispecific CLEC12AxCD3 T-cell engager in patients with acute myelogenous leukemia.","author":"Mascarenhas","year":"2020"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.52","article-title":"CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia","volume":"29","author":"Kenderian","year":"2015","journal-title":"Leukemia"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor\u2013modified T cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-20-0208","article-title":"NOT-gated CD93 CAR T cells effectively target AML with minimized endothelial cross-reactivity","volume":"2","author":"Richards","year":"2021","journal-title":"Blood Cancer Discovery"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008762","article-title":"IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML","volume":"7","author":"Perriello","year":"2023","journal-title":"Blood Adv"},{"key":"B123","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1182\/blood-2018-99-110579","article-title":"First-in-human CLL1-CD33 compound CAR T cell therapy induces complete remission in patients with refractory acute myeloid leukemia: update on phase 1 clinical trial","volume":"132","author":"Liu","year":"2018","journal-title":"Blood"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-170201","article-title":"Safety and anti-leukemic activity of CD123-CAR T cells in pediatric patients with AML: preliminary results from a phase 1 trial","volume":"140","author":"Naik","year":"2022","journal-title":"Blood"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01232-2","article-title":"Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia","volume":"35","author":"Tambaro","year":"2021","journal-title":"Leukemia"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03422-6","article-title":"Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia","volume":"72","author":"Cheng","year":"2023","journal-title":"Cancer Immunol Immunother."},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008221","article-title":"CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity","volume":"138","author":"Sauer","year":"2021","journal-title":"Blood"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(90)90097-S","article-title":"In search of the \u201cmissing self\u201d: MHC molecules and NK cell recognition","volume":"11","author":"Ljunggren","year":"1990","journal-title":"Immunol Today"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat Rev Cancer."},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"B131","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1055\/s-0042-1748710","article-title":"Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia","volume":"12","author":"Albinger","year":"2022","journal-title":"Blood Cancer J"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15691","article-title":"Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT","volume":"184","author":"Schmid","year":"2019","journal-title":"Br J Haematol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"key":"B134","article-title":"Adoptive immunotherapy of acute leukemia: experimental and clinical results","volume":"25","author":"Math\u00e9","year":"1965","journal-title":"Cancer Res"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0811036","article-title":"Loss of mismatched HLA in leukemia after stem-cell transplantation","volume":"361","author":"Vago","year":"2009","journal-title":"New Engl J Med"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"New Engl J Med"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000445","article-title":"Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation","volume":"3","author":"Jan","year":"2019","journal-title":"Blood Adv"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.10","article-title":"5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft","volume":"50","author":"Steinmann","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3109\/02656736.2012.722263","article-title":"Pathological complete response and sphincter-sparing surgery after neoadjuvant radiochemotherapy with regional hyperthermia for locally advanced rectal cancer compared with radiochemotherapy alone","volume":"28","author":"Schroeder","year":"2012","journal-title":"Int J Hyperthermia."},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.140996","article-title":"Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia","volume":"101","author":"Craddock","year":"2016","journal-title":"Haematologica"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-572743","article-title":"Both mature KIR+ and immature KIR\u2013 NK cells control pediatric acute B-cell precursor leukemia in NOD.Cg-Prkdcscid IL2rgtmWjl\/Sz mice","volume":"124","author":"K\u00fcbler","year":"2014","journal-title":"Blood"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts","volume":"162","author":"Roulois","year":"2015","journal-title":"Cell"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6213","article-title":"Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome","volume":"6","author":"Sohlberg","year":"2015","journal-title":"Oncotarget"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1038\/nature15520","article-title":"Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy","volume":"527","author":"Peng","year":"2015","journal-title":"Nature"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.074823","article-title":"The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome","volume":"98","author":"Costantini","year":"2013","journal-title":"Haematologica"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3324","article-title":"Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS\/AML patients: A rationale for combined targeting of PD-1 and DNA methylation","volume":"6","author":"\u00d8rskov","year":"2015","journal-title":"Oncotarget"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: A nonrandomized, open-label, phase II study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discovery."},{"key":"B150","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1182\/blood-2019-127345","article-title":"Multi-center phase 2 study of pembroluzimab (Pembro) and azacitidine (AZA) in patients with relapsed\/refractory acute myeloid leukemia (AML) and in newly diagnosed (\u226565 years) AML patients","volume":"134","author":"Gojo","year":"2019","journal-title":"Blood"},{"key":"B151","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1182\/blood-2021-146039","article-title":"Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (Pts) with very high\/high-risk myelodysplastic syndrome (vHR\/HR-MDS) and acute myeloid leukemia (AML): final analysis from a phase ib study","volume":"138","author":"Brunner","year":"2021","journal-title":"Blood"},{"key":"B152","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1182\/blood-2019-122896","article-title":"Efficacy and safety of azacitidine (AZA) in combination with the anti-PD-L1 durvalumab (durva) for the front-line treatment of older patients (pts) with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy (IC) and pts with higher-risk myelodysplastic syndromes (HR-MDS): results from a large, international, randomized phase 2 study","volume":"134","author":"Zeidan","year":"2019","journal-title":"Blood"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.882531","article-title":"Immune checkpoint inhibitors in acute myeloid leukemia: A meta-analysis","volume":"12","author":"G\u00f3mez-Llobell","year":"2022","journal-title":"Front Oncol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.78","article-title":"Severe acute GvHD following administration of ipilimumab for early relapse of AML after haploidentical stem cell transplantation","volume":"52","author":"Gros","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33690","article-title":"A phase 1b\/2 study of azacitidine with PD-L1 antibody avelumab in relapsed\/refractory acute myeloid leukemia","volume":"127","author":"Saxena","year":"2021","journal-title":"Cancer"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0077-T","article-title":"HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade","volume":"3","author":"Woods","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-05-0229","article-title":"Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3 , and -A12 in human cancer cells","volume":"4","author":"Wischnewski","year":"2006","journal-title":"Mol Cancer Res"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.12.7017","article-title":"Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors","volume":"165","author":"Magner","year":"2000","journal-title":"J Immunol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2584","article-title":"HDAC inhibitors enhance T-cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma","volume":"22","author":"Zheng","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B160","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/cancers14010066","article-title":"HDAC inhibition to prime immune checkpoint inhibitors","volume":"14","author":"Borcoman","year":"2021","journal-title":"Cancers (Basel)."},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158626","article-title":"A multi-center phase ib trial of the histone deactylase inhibitor (HDACi) entinostat in combination with anti-PD1 antibody pembrolizumab in patients with refractory\/relapsed myelodysplastic syndromes (RR-MDS) or oligoblastic acute myeloid leukemia (RR-AML) after hypomethylating agent (HMA) failure","volume":"140","author":"Bewersdorf","year":"2022","journal-title":"Blood"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-170188","article-title":"Phase I\/II study of azacitidine (AZA) with venetoclax (VEN) and magrolimab (Magro) in patients (pts) with newly diagnosed (ND) older\/unfit or high-risk acute myeloid leukemia (AML) and relapsed\/refractory (R\/R) AML","volume":"140","author":"Daver","year":"2022","journal-title":"Blood"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-527044","article-title":"Cellular determinants for preclinical activity of a novel CD33\/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML","volume":"123","author":"Laszlo","year":"2014","journal-title":"Blood"},{"key":"B164","doi-asserted-by":"publisher","first-page":"6436","DOI":"10.1038\/s41467-021-26683-0","article-title":"Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia","volume":"12","author":"El Khawanky","year":"2021","journal-title":"Nat Commun"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0910-8","article-title":"Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents","volume":"26","author":"Riether","year":"2020","journal-title":"Nat Med"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1145441","article-title":"Demethylating therapy increases cytotoxicity of CD44v6 CAR-T cells against acute myeloid leukemia","volume":"14","author":"Tang","year":"2023","journal-title":"Front Immunol"},{"key":"B167","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/gene.2014.58","article-title":"Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia","volume":"16","author":"Baraga\u00f1o Raneros","year":"2015","journal-title":"Genes Immun"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1410-1","article-title":"Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion","volume":"572","author":"Paczulla","year":"2019","journal-title":"Nature"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2007.02.020","article-title":"Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis","volume":"31","author":"Rohner","year":"2007","journal-title":"Leuk Res"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-680546","article-title":"Decitabine enhances anti-CD33 monoclonal antibody BI 836858\u2013mediated natural killer ADCC against AML blasts","volume":"127","author":"Vasu","year":"2016","journal-title":"Blood"},{"key":"B171","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41375-020-0773-5","article-title":"Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2\/3 study","volume":"35","author":"Montesinos","year":"2021","journal-title":"Leukemia"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0009-0","article-title":"CAR T-cells targeting FLT3 have potent activity against FLT3-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib","volume":"32","author":"Jetani","year":"2018","journal-title":"Leukemia"},{"key":"B173","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41419-022-05123-x","article-title":"BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia","volume":"13","author":"Zhong","year":"2022","journal-title":"Cell Death Dis"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1172\/JCI86437","article-title":"BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models","volume":"126","author":"Kagoya","year":"2016","journal-title":"J Clin Invest."},{"key":"B175","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cell.2018.05.052","article-title":"LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade","volume":"174","author":"Sheng","year":"2018","journal-title":"Cell"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0070-8","article-title":"Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes","volume":"32","author":"Daver","year":"2018","journal-title":"Leukemia"},{"key":"B177","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1182\/blood-2021-145208","article-title":"A phase 3, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with azacitidine in previously untreated patients with TP53-mutant acute myeloid leukemia","volume":"138","author":"Daver","year":"2021","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1269012\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T06:15:40Z","timestamp":1695363340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1269012\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,22]]},"references-count":177,"alternative-id":["10.3389\/fimmu.2023.1269012"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1269012","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,22]]},"article-number":"1269012"}}